Actavis plc reports that G. Frederick Wilkinson , President, Actavis Global R&D, will leave the company effective April 25, 2014. Wilkinson has accepted the position of President and Chief Executive Officer at the specialty pharmaceutical company Impax Laboratories, Inc. He succeeds Larry Hsu, who is retiring.

Wilkinson was appointed president, Global R&D on January of 2014. He joined then Watson as Executive Vice President, Global Brands in September 2009 and was appointed President of Global Specialty Brands in January 2013.

Actavis Global R&D will report to Robert Stewart , President, Actavis Global Operations

Source: Actavis and Impax Laboratories